State Street SPDR S&P Biotech ETF (XBI)
| Assets | $10.69B |
| Expense Ratio | 0.35% |
| PE Ratio | 22.00 |
| Forward PE | 20.82 |
| Shares Out | 69.53M |
| Dividend | $0.54 (0.36%) |
| Ex-Dividend Date | Jun 22, 2026 |
| Payout Frequency | n/a |
| Payout Ratio | 7.90% |
| Volume | 11,603,428 |
| Open | 152.03 |
| Previous Close | 152.78 |
| Day's Range | 149.70 - 154.39 |
| 52-Week Low | 106.30 |
| 52-Week High | 169.89 |
| Beta | 0.83 |
| Holdings | 167 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe State Street SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
18.01% of assets| Name | Symbol | Weight |
|---|---|---|
| Moderna, Inc. | MRNA | 2.69% |
| Natera, Inc. | NTRA | 1.86% |
| Twist Bioscience Corporation | TWST | 1.76% |
| Halozyme Therapeutics, Inc. | HALO | 1.72% |
| Biogen Inc. | BIIB | 1.70% |
| AbbVie Inc. | ABBV | 1.68% |
| Amgen Inc. | AMGN | 1.66% |
| Iovance Biotherapeutics, Inc. | IOVA | 1.65% |
| United Therapeutics Corporation | UTHR | 1.65% |
| Exelixis, Inc. | EXEL | 1.64% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 22, 2026 | $0.13809 | Jun 24, 2026 |
| Dec 22, 2025 | $0.40656 | Dec 24, 2025 |
| Sep 22, 2025 | $0.02665 | Sep 24, 2025 |
| Jun 23, 2025 | $0.0073 | Jun 25, 2025 |
| Mar 24, 2025 | $0.00525 | Mar 26, 2025 |
| Dec 23, 2024 | $0.00269 | Dec 26, 2024 |
Performance
XBI had a total return of 39.00% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.61%.
News
From Laggard to Leader: The Surprising Comeback of Healthcare
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's mo...
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big p...
Pharmaceutical trade group sues Trump administration
Pharmaceutical Research and Manufacturers of America, the pharmaceutical industry lobbying group, sued the Trump administration on Wednesday, court records show.
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
XBI Forecast: $174.79 Tests Biotech ETF Breakout Strength
XBI approaches its 2021 high at $174.79 after a bullish flag breakout, setting up a key test between further gains and a potential consolidation.
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Market rotation is the most prevalent factor for healthcare outperformance, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss the recent performance in the healthcare sector, why sentiment has turned and much more.
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
‘Buying stuff like it's going out of fashion': Biotech M&A on track for best year since pre-Covid
So far in 2026, biotech deals amounted to $106 billion over 201 transactions, according to PitchBook data. That momentum in dealmaking comes despite an interest rate environment that has turned for th...
Biotech Investors Are Tuning Out the MAHA Chaos
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
SPDR S&P Biotech ETF (XBI) Price Forecast: Long-Term Breakout Fuels Biotech Strength
XBI continues to strengthen following a multi-month breakout, with bullish trend signals supporting upside targets near key Fibonacci retracement resistance levels.
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
The biotech sector took a hit this week despite a recent spike in search activity. The SPDR S&P Biotech ETF ($XBI) and iShares Biotechnology ETF ($IBB) declined slightly, while two…
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
The SPDR S&P Biotech ETF ($XBI) is drawing fresh investor attention as analysts maintain a bullish outlook on some of its underlying holdings. The fund, which tracks an equal-weighted index…
Funding for Risky Biotechs Is Returning
Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.
Why 2026 may be a strong year for biotech stocks
Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid-cap biotech names – posting one of its strongest stretches on record. Mizu...
Mizuho's Jared Holz on why he is bullish on biotech heading into 2026
Jared Holz, Mizuho, joins 'Power Lunch' to talk how to play healthcare and biotech moving into 2026.
Final Trades: Toast, Uber, the XLB and the XBI
The Investment Committee reveals the stocks they're watching as the market sets up for its next move.
The Fed cut rates. Biotech didn't notice.
Biotechs are instead spending their time advancing the kind of smart science that will catch the eye of cash-rich pharmaceutical companies.
Final Trades: FTAI, ETN, COWZ, XBI
The Investment Committee give you their top stocks to watch for the second half.